Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2013

Open Access 01-12-2013 | Research article

MDR1polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients

Authors: Marko Brinar, Silvija Cukovic-Cavka, Nada Bozina, Katja Grubelic Ravic, Pave Markos, Agata Ladic, Marijana Cota, Zeljko Krznaric, Boris Vucelic

Published in: BMC Gastroenterology | Issue 1/2013

Login to get access

Abstract

Background

Inflammatory bowel diseases (IBD) are chronic diseases of unknown etiology and pathogenesis in which genetic factors contribute to development of disease. MDR1/ABCB1 is an interesting candidate gene for IBD. The role of two single nucleotide polymorphisms, C3435T and G2677T remains unclear due to contradictory results of current studies. Thus, the aims of this research were to investigate the association of MDR1 polymorphisms, C3435T and G2677T, and IBD.

Methods

A total of 310 IBD patients, 199 Crohn's disease (CD) patients and 109 ulcerative colitis (UC) patients, and 120 healthy controls were included in the study. All subjects were genotyped for G2677T/A and C3435T polymorphism using RT-PCR. In IBD patients, review of medical records was performed and patients were phenotyped according to the Montreal classification.

Results

Significantly higher frequency of 2677T allele (p = 0.05; OR 1.46, 95% CI (1.0-2.14)) and of the 3435TT genotype was observed among UC patients compared to controls (p = 0.02; OR 2.12; 95% CI (1.11-4.03). Heterozygous carriers for C3435T were significantly less likely to have CD (p = 0.02; OR 0.58, 95% CI (0.36-0.91)). Haplotype analysis revealed that carriers of 3435T/2677T haplotype had a significantly higher risk of having UC (p = 0.02; OR 1.55; 95% CI (1.06-2.28)).

Conclusion

MDR1 polymorphisms are associated with both CD and UC with a stronger association with UC.
Literature
1.
Andres PG, Friedman LS: Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999, 28: 81-255. 10.1097/00004836-199901000-00022. viiCrossRef
2.
Juliano RL, Ling V: A surface glycoprotein modulating drug pereability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976, 455: 152-162. 10.1016/0005-2736(76)90160-7.CrossRefPubMed
3.
Thiebaut F, Tsuoro T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localisation of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987, 84: 7735-7738. 10.1073/pnas.84.21.7735.CrossRefPubMedPubMedCentral
4.
Cordon-Cardo O, O'Brien JP, Casals D, Rittmen-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-gylcoprotein) is expressed by endothelial cells at the blood–brain barrier sites. Procl Natl Acad Sci USA. 1989, 86: 695-698. 10.1073/pnas.86.2.695.CrossRef
5.
Ho GT, Moodie FM, Satsangi J: Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant of gastrointestinal disease?. Gut. 2003, 52: 759-766. 10.1136/gut.52.5.759.CrossRefPubMedPubMedCentral
6.
Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A; in vitro-in vivo correlation. Br J Pharmacol. 1996, 118: 1841-1847. 10.1111/j.1476-5381.1996.tb15612.x.CrossRefPubMedPubMedCentral
7.
Chianale J, Vollrath V, Wielandt AM, Miranda S, Gonzalez R, Fresno AM, Quintana C, Gonzalez S, Andrade R, Guzman L: Differences between nuclear run-off and mRNA levels for multidrug resistance gene expression in the cephalocaudal axis of the mouse intestine. Biochim Biophys Acta. 1995, 1264: 369-376. 10.1016/0167-4781(95)00179-4.CrossRefPubMed
8.
Panwala CM, Jones JC, Viney JL: A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontanously develop colitis. J Immunol. 1998, 161: 5733-5744.PubMed
9.
Van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD: Lewis CM; Genome scan meta-analysis group of the IBD International genetics consortium. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet. 2004, 13: 763-770. 10.1093/hmg/ddh090.CrossRefPubMed
10.
Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, Schmitz G: Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004, 127: 26-40. 10.1053/j.gastro.2004.04.019.CrossRefPubMed
11.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human mutidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein activity in vivo. Proc Natl Acad Sci USA. 2000, 97: 3473-3478. 10.1073/pnas.97.7.3473.CrossRefPubMedPubMedCentral
12.
Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K: Expression of P-glycoprotein in human placenta: relation to genetic polymorphisms of the mutidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001, 297: 1137-1143.PubMed
13.
Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K: Effect of mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002, 71: 297-303. 10.1067/mcp.2002.122055.CrossRefPubMed
14.
Kim RB, Leake BF, Choo EF: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharamcol Ther. 2001, 70: 189-199. 10.1067/mcp.2001.117412.CrossRef
15.
Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M: Association between the C3434T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003, 124: 26-33. 10.1053/gast.2003.50010.CrossRefPubMed
16.
Croucher PJ, Mascheretti S, Foelsch UR, Hampe J, Schreiber S: Lack of association between the C3435T MDR 1 gene polymorphisms and inflammatory bowel disease in two independent Northern European populations. Gastroenterology. 2003, 125: 1919-1920. 10.1053/j.gastro.2003.05.016.CrossRefPubMed
17.
Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003, 73: 1282-1292. 10.1086/379927.CrossRefPubMedPubMedCentral
18.
Glas J, Török HP, Schiemann U, Folwaczny C: MDR1 gene polymorphism in ulcerative colitis. Gastroenterology. 2004, 126: 367-CrossRefPubMed
19.
Gazouli M, Zacharatos P, Gorgoulis V, Mantzaris G, Papalambros E, Ikonomopoulos J: The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology. 2004, 126: 367-369.CrossRefPubMed
20.
Potocnik U, Ferkolj I, Glavač D, Dean M: Polymorphisms in mutidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 2004, 5: 530-539. 10.1038/sj.gene.6364123.CrossRefPubMed
21.
Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, Arnott ID, Satsangi J: Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005, 128: 288-296. 10.1053/j.gastro.2004.11.019.CrossRefPubMed
22.
Palmieri O, Latiano A, Valvano R, D'Incà R, Vecchi M, Sturniolo GC, Saibeni S, Bossa F, Latiano T, Devoto M, Andriulli A, Annese V: Multidrug resistance gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005, 22 (11–12): 1129-1138.CrossRefPubMed
23.
Onnie CM, Fisher SA, Pattni R, Sanderson J, Forbes A, Lewis CM, Mathew CG: Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behaviour: A case control study and meta-analyis study. Inflamm Bowel Dis. 2006, 12: 263-271. 10.1097/01.MIB.0000209791.98866.ba.CrossRefPubMed
24.
Urcelay E, Mendoza JL, Martín MC, Mas A, Martínez A, Taxonera C, Fernandez-Arquero M, Díaz-Rubio M, de la Cocha EG: MDR1 gene: Susceptibility in Spanish Crohn's disease and ulcerative colitis patients. Inflamm Bowel Dis. 2006, 12: 33-37. 10.1097/01.MIB.0000194184.92671.78.CrossRefPubMed
25.
Oostenbrug LE, Dijkstra G, Nolte IM, van Dullemen HM, Oosterom E, Faber KN, de Jong DJ, van der Linde K, te Meerman GJ, van der Steege G, Kleibeuker JH, Jansen PL: Absence of association between the mutidrug resistance (MDR1) gene and inflammatory bowel disease. Scand J Gastroenterol. 2006, 41: 1174-1182. 10.1080/00365520600575746.CrossRefPubMed
26.
Lal S, Stempak JM, Law C, Elkadri AA, Steinhart AH, Silverberg MS: Association between the C3435T polymorphism of the MDR1 gene and Crohn's disease. Inflamm Bowel Dis. 2006, 12: 1006-10.1097/01.mib.0000228999.37090.e1.CrossRefPubMed
27.
Fischer S: Lakatos LP; Hungarian IBD Study Group, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szilvasi A, Tulassay Z, Osztovits J, Papp J, Demeter P, Schwab R, Tordai A, Andrikovics H. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype, response to medical therapy or need for surgery in Hungarian patients with inflammatory bowel disease. Scand J Gastroenterol. 2007, 42: 726-733. 10.1080/00365520601101559.CrossRefPubMed
28.
Fiedler T, Büning C, Reuter W, Pitre G, Gentz E, Schmidt HH, Büttner J, Ockenga J, Gerloff T, Meisel C, Lochs H, Roots I, Köpke K, Johne A: Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. Eur J Clin Pharmacol. 2007, 63: 917-925. 10.1007/s00228-007-0334-0.CrossRefPubMed
29.
Ardizzone S, Maconi G, Bianchi V, Russo A, Colombo E, Cassinotti A, Penati C, Tenchini ML, Bianchi PG: Multidrug resistance gene 1 polymorphism and susceptibility to inflammatory bowel disease. Inflamm Bowel Dis. 2007, 13: 516-523. 10.1002/ibd.20108.CrossRefPubMed
30.
Huebner C, Browning BL, Petermann I, Han DY, Philpott M, Barclay M, Gearry R, McCulloch A, Demmers P, Ferguson LR: Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflamm Bowel Dis. 2009, 15: 1784-1793. 10.1002/ibd.21019.CrossRefPubMed
31.
Silverberg MS, Satsangi J, Ahmad T: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005, 19 (Suppl A): 5-36.CrossRef
32.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cell. Nucl Acid Res. 1988, 16: 1215-10.1093/nar/16.3.1215.CrossRef
33.
Arjomand-Nahad F, Diefenbach K, Landt O, Gaikovitch E, Roots I: Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem. 2004, 334: 201-203. 10.1016/j.ab.2004.07.030.CrossRefPubMed
34.
Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I: MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol. 2003, 17: 463-469. 10.1046/j.1472-8206.2003.00163.x.CrossRefPubMed
35.
von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001, 47: 1048-1052.PubMed
36.
Excoffier L, Slatkin M: Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol. 1995, 12: 921-927.PubMed
37.
Kimchi-Sarfaty C, Gribar JJ, Gottesman MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol. 2002, 62: 1-6. 10.1124/mol.62.1.1.CrossRefPubMed
38.
Wang D, Johnson AD, Papp AC: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics. 2005, 15: 693-703. 10.1097/01.fpc.0000178311.02878.83.CrossRefPubMed
Metadata
Title
MDR1polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients
Authors
Marko Brinar
Silvija Cukovic-Cavka
Nada Bozina
Katja Grubelic Ravic
Pave Markos
Agata Ladic
Marijana Cota
Zeljko Krznaric
Boris Vucelic
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2013
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-13-57

Other articles of this Issue 1/2013

BMC Gastroenterology 1/2013 Go to the issue

Research article

Impaired mitochondrial β-oxidation in patients with chronic hepatitis C: relation with viral load and insulin resistance

Research article

Physiologic and laboratory correlates of depression, anxiety, and poor sleep in liver cirrhosis

Research article

Low rate of recurrence of Helicobacter Pylori infection in spite of high clarithromycin resistance in Pakistan

Research article

Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study

Research article

A randomised controlled trial of a probiotic ‘functional food’ in the management of irritable bowel syndrome

Research article

Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits